GoodRx (NASDAQ:GDRX) Shares Gap Up - Time to Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $4.11, but opened at $4.26. GoodRx shares last traded at $4.46, with a volume of 627,638 shares.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on GDRX shares. The Goldman Sachs Group decreased their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Truist Financial decreased their target price on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a report on Thursday, April 10th. Wells Fargo & Company decreased their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Finally, UBS Group decreased their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $6.55.

GoodRx Price Performance

The business's 50 day moving average price is $4.27 and its 200 day moving average price is $4.53. The stock has a market capitalization of $1.56 billion, a P/E ratio of -145.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. During the same period in the previous year, the business posted $0.08 earnings per share. The business's revenue for the quarter was up 2.6% on a year-over-year basis. Sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $4.09, for a total transaction of $43,668.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is currently owned by company insiders.

Institutional Trading of GoodRx

Several large investors have recently added to or reduced their stakes in GDRX. National Bank of Canada FI grew its position in GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after buying an additional 2,151 shares during the period. Citizens Financial Group Inc. RI bought a new stake in GoodRx during the first quarter valued at approximately $44,000. Jump Financial LLC purchased a new position in GoodRx during the first quarter valued at approximately $49,000. RPO LLC purchased a new position in GoodRx during the fourth quarter valued at approximately $52,000. Finally, Versor Investments LP purchased a new position in GoodRx during the fourth quarter valued at approximately $54,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.